---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-083280"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2024-07-29T23:59:59+00:00"
generated_at: "2026-05-31T15:41:26.700706+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Cognition Therapeutics files investor presentation on Phase 2 SHINE results for CT1812 Alzheimer's study

## Summary
- Phase 2 proof-of-concept SHINE study of CT1812 in mild-to-moderate Alzheimer's disease.
- Results presented on July 29, 2024 via investor presentation filed as exhibit.
- No specific efficacy or safety endpoints disclosed in the 8-K filing text.

## SEC filing metadata
- accession: 0001104659-24-083280
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2024-07-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465924083280/0001104659-24-083280-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465924083280/tm2420336d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-083280
- JSON: https://secwatch.observer/filing/0001104659-24-083280.json
- Plain text: https://secwatch.observer/filing/0001104659-24-083280.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.